Atazanavir Sulfate; Cobicistat Patent Expiration
Atazanavir Sulfate; Cobicistat is Used for treating HIV-1 infection by including a pharmacokinetic enhancer that inhibits cytochrome P450 monooxygenase. It was first introduced by Bristol Myers Squibb Co
Atazanavir Sulfate; Cobicistat Patents
Given below is the list of patents protecting Atazanavir Sulfate; Cobicistat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Evotaz | US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Oct 06, 2032 | Bristol |
| Evotaz | US5849911 | Antivirally active heterocyclic azahexane derivatives |
Jun 20, 2017
(Expired) | Bristol |
| Evotaz |
US5849911 (Pediatric) | Antivirally active heterocyclic azahexane derivatives |
Dec 20, 2017
(Expired) | Bristol |
| Evotaz | US6087383 | Bisulfate salt of HIV protease inhibitor |
Dec 21, 2018
(Expired) | Bristol |
| Evotaz |
US6087383 (Pediatric) | Bisulfate salt of HIV protease inhibitor |
Jun 21, 2019
(Expired) | Bristol |
| Evotaz | US8148374 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Bristol |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳